Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024
Journal of Antimicrobial Chemotherapy · 2025
DOI: 10.1093/jac/dkaf255 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2025. Verfasst von Jinjin Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People's Hospital of Zhengzhou), Trans…. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Anti-HIV Agents. Die Arbeit nennt 24 Literaturangaben. Gefördert von: Science and Technology Project of Henan Province, Medical Scientific Research Project of Zhengzhou City.
Abstract (Originalsprache)
Background
Following with the widespread adoption of antiretroviral treatment (ART) for human immunodeficiency virus type 1 (HIV-1), the prevalence of transmitted drug resistance (TDR) among newly diagnosed people living HIV-1 (PLWH) has shown an upward trend. Thus, a close monitoring of TDR can provide valuable data for local management of PLWH. Materials and methods Plasma samples were collected from newly diagnosed PLWH seeking treatments in the Sixth People’s Hospital of Zhengzhou from Jan 2024 to December 2024. The partial pol and the complete integrase gene coding sequences were separately amplified, sequenced, and analysed.
Results
Of a total of 1249 patients, we obtained partial pol sequences from 1227 patients and integrase sequences from 1224 patients. Subtyping analysis showed predominance of CRF07_BC (41.73%, 512/1227), followed by CRF01_AE (27.06%, 332/1227), B (21.35%, 262/1227), CRF55_01B (4.81%, 59/1227), and CRF08_BC (1.96%, 24/1227). Transmitted drug resistance mutations were detected in 137 patients, giving a TDR prevalence of 11.25% (137/1227). The most frequently detected mutations leading to low-level or above drug resistance against nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, protease inhibitors, and integrase transfer inhibitors were M184I/V, K103N/S, M46I/L/V, and E138A, respectively. The prevalence of TDR remained at a modest level and showed no significant difference when compared with previous years.
Conclusions
Genotypic drug resistance testing is recommended for newly diagnosed PLWH before the initiation of ART to provide effective treatment regimens.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Affiliated Infectious Diseases Hospital of Zhengzhou University (Henan Infectious Diseases Hospital, the Sixth People's Hospital of Zhengzhou), Translational Medicine Research Center, Zhengzhou 450000, People's Republic…
ORCID-Profile: Jinjin Liu, Yuqi Huo
Förderung
- Science and Technology Project of Henan Province
- Medical Scientific Research Project of Zhengzhou City
Zitieren
APA
Liu, J., Yang, X., Deng, X., Hou, M., Wei, S., Zhang, X., Huo, Y., & Zhao, Q. (2025). Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf255
Vancouver
Liu J, Yang X, Deng X, Hou M, Wei S, Zhang X, et al. Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf255
BibTeX
@article{Liu2025,
author = {Liu, Jinjin and Yang, Xuan and Deng, Xin and Hou, Mingjie and Wei, Shuguang and Zhang, Xiaohua and Huo, Yuqi and Zhao, Qingxia},
title = {Transmitted drug resistance profiles among people living with HIV-1 in Henan province, China, 2024},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2025},
doi = {10.1093/jac/dkaf255}
}
EUVIMED